Pyros Pharmaceuticals, Inc., a leading company in the development of specialty pharmaceuticals for rare diseases, has announced the availability of VIGPODER™ (vigabatrin) for oral solution, USP, for the treatment of appropriate patients with infantile spasms (IS). VIGPODER™ provides a therapeutically equivalent, affordable treatment option with a safety and efficacy profile anticipated to be the same as SABRIL® (vigabatrin) for oral solution.
Infantile spasms represent a significant challenge for patients and their families due to the rarity and severity of this form of epilepsy. Through the introduction of VIGPODER™, Pyros aims to ensure that families confronted with an IS diagnosis have rapid access to this essential therapy. The company is further committed to supporting these families through its Pyros Total Care™ program, offering personalized comprehensive support and assistance throughout their treatment journey.
Pyros Total Care™ offers personalized assistance and financial resources, including support from a dedicated nurse educator, reimbursement support, and clinical pharmacist advice. It underscores Pyros’ commitment to facilitating treatment access and providing comprehensive support to caregivers navigating the challenges of infantile spasms.
Infantile spasms (IS) is a rare, severe form of epilepsy primarily affecting children under one year old. The condition can manifest as subtle, repetitive movements that may be easily overlooked or misdiagnosed. Without appropriate treatment, IS can lead to continued seizures, other forms of epilepsy, autism spectrum disorder, and developmental issues. The American Academy of Neurology emphasizes that successful treatment of IS can significantly improve the long-term prognosis for affected children.
Vigabatrin, the active ingredient in VIGPODER™, is a medication designed to inhibit GABA transaminase, increasing gamma-aminobutyric acid (GABA) levels in the brain. This mechanism is thought to contribute to seizure control by modulating neuronal excitability, underscoring the role of vigabatrin in managing seizure disorders, including infantile spasms.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
